We have 200m shares. Even if they sold them all ri
Post# of 148243
It's obviously true we need revenue and/or a partner, and there are debts (as with any pre-rev biotech), but money's not as tight as some posit. I certainly don't think they stopped or slowed Brazil critical trial because of money. That trial could be the quickest to generate an EUA and revenue.